Novel Treatment for Diabetes - Focusing on GLP-1 and SGLT2


Efficacy and Safety of Switching from Sitagliptin to Liraglutide in Subjects with Type 2 Diabetes: A Randomized, Double-Blind, Double-Dummy, Active-Controlled 26-Week Trial
Timothy S Bailey, Róbert Takács, Francisco Tinahones Madueño, Anne Bloch Thomsen, Margit Staum Kaltoft and Maximo Maislos


Fibroblast Growth Factor 21 As a Biomarker Is Superior to Adiponectin in the Prediction of Incident Diabetes
Yu Cho Woo, Chi Ho Lee, Carol HY Fong, Aimin Xu, Annette Tso, Bernard MY Cheung and Karen SL Lam